Stockreport

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

Palvella Therapeutics, Inc.  (PVLA) 
PDF Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious [Read more]